BioSpace News Archive

The U.S. Food and Drug Administration has granted ENHERTU® Breakthrough Therapy Designation in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2-based regimens.

Sodium hyaluronate eye drops, also known as artificial tears, are used to relieve eye soreness and dryness. Sodium hyaluronate eye drops smoothen, moisten, and lubricate the eye surface and is widely recommended.

Root canal sealers are utilized to seal space between the dentinal divider and obturating center interface.

Non-insulin treatments are generally utilized in type 2 diabetes patients, where body either doesn’t deliver enough insulin or can’t successfully utilize the insulin it produces.

Catheter is a long thin tube inserted in the body to treat or perform surgical procedure. Treatment of neurovascular conditions requires specialized and miniature delivery access systems.

Carcinoembryonic antigen (CEA) is a protein usually produced in developing fetus and disappears or is absent in adults. Production of abnormal amount of CEA protein could lead to cancer.

Debiopharm, a Swiss-based global biopharmaceutical company, announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Shumpei Ishikawa and Translational Research – Dr. Hiromichi Ebi.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced enrollment has been completed in the Phase III EVOLUTION RMS clinical trial program, which is evaluating the efficacy and safety of investigational Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis.

ViaDerma, Inc., is pleased to announce they are launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra.

Zomedica Corp., a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, announced that Larry Heaton has been appointed President effective October 1, 2021.